Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells

Daron Street, Andreas M. Kaufmann, Andrew T M Vaughan, Susan G. Fisher, Michael Hunter, Carola Schreckenberger, Ronald K. Potkul, Lutz Gissmann, Liang Qiao

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Recently we have demonstrated that tumor-specific cytotoxic T lymphocytes (Culs) can be activated by cervical carcinoma cells expressing the costimulatory molecule CD80, which may be used as a therapeutic vaccine for patients with cervical cancer. For activated Culs to be effective, appropriate amounts of MHC class I expression are required on target tumor cells. In this study, we found that some cervical carcinoma cells expressed only low levels of MHC class 1 and adhesion molecules such as CD54. We further demonstrated that tumor cells (CaSki and SiHa) expressing low levels of MHC class 1 were more resistant to lysis by specific Culs than tumor cells (HeLa) expressing high levels of MHC class I. Treatment of CaSki or SiHa cells with interferon-γ resulted in n increased expression of MHC class I, MHC class II, and CD54. Expression of CD58 and CD80 was not up-regulated or induced. Treatment of the tumor cells with interferon-γ significantly enhanced the lysis of the tumor cells by specific Culs which had been activated by the respective CD80-expressing tumor cells. The enhancement of cytolysis could be blocked by monoclonal antibodies to MHC class I and CD54, but not by that to MHC class II. Furthermore, we found that interferon-γ induced apoptosis in cervical carcinoma cells but not in tumor-specific Culs.

Original languageEnglish (US)
Pages (from-to)265-272
Number of pages8
JournalGynecologic Oncology
Volume65
Issue number2
DOIs
StatePublished - May 1997
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Interferons
T-Lymphocytes
Neoplasms
Carcinoma
Cytotoxic T-Lymphocytes
HeLa Cells
Therapeutics
Vaccines
Monoclonal Antibodies
Apoptosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. / Street, Daron; Kaufmann, Andreas M.; Vaughan, Andrew T M; Fisher, Susan G.; Hunter, Michael; Schreckenberger, Carola; Potkul, Ronald K.; Gissmann, Lutz; Qiao, Liang.

In: Gynecologic Oncology, Vol. 65, No. 2, 05.1997, p. 265-272.

Research output: Contribution to journalArticle

Street, D, Kaufmann, AM, Vaughan, ATM, Fisher, SG, Hunter, M, Schreckenberger, C, Potkul, RK, Gissmann, L & Qiao, L 1997, 'Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells', Gynecologic Oncology, vol. 65, no. 2, pp. 265-272. https://doi.org/10.1006/gyno.1997.4667
Street, Daron ; Kaufmann, Andreas M. ; Vaughan, Andrew T M ; Fisher, Susan G. ; Hunter, Michael ; Schreckenberger, Carola ; Potkul, Ronald K. ; Gissmann, Lutz ; Qiao, Liang. / Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. In: Gynecologic Oncology. 1997 ; Vol. 65, No. 2. pp. 265-272.
@article{9f596a516cd24ab196d63d31a5c0eeda,
title = "Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells",
abstract = "Recently we have demonstrated that tumor-specific cytotoxic T lymphocytes (Culs) can be activated by cervical carcinoma cells expressing the costimulatory molecule CD80, which may be used as a therapeutic vaccine for patients with cervical cancer. For activated Culs to be effective, appropriate amounts of MHC class I expression are required on target tumor cells. In this study, we found that some cervical carcinoma cells expressed only low levels of MHC class 1 and adhesion molecules such as CD54. We further demonstrated that tumor cells (CaSki and SiHa) expressing low levels of MHC class 1 were more resistant to lysis by specific Culs than tumor cells (HeLa) expressing high levels of MHC class I. Treatment of CaSki or SiHa cells with interferon-γ resulted in n increased expression of MHC class I, MHC class II, and CD54. Expression of CD58 and CD80 was not up-regulated or induced. Treatment of the tumor cells with interferon-γ significantly enhanced the lysis of the tumor cells by specific Culs which had been activated by the respective CD80-expressing tumor cells. The enhancement of cytolysis could be blocked by monoclonal antibodies to MHC class I and CD54, but not by that to MHC class II. Furthermore, we found that interferon-γ induced apoptosis in cervical carcinoma cells but not in tumor-specific Culs.",
author = "Daron Street and Kaufmann, {Andreas M.} and Vaughan, {Andrew T M} and Fisher, {Susan G.} and Michael Hunter and Carola Schreckenberger and Potkul, {Ronald K.} and Lutz Gissmann and Liang Qiao",
year = "1997",
month = "5",
doi = "10.1006/gyno.1997.4667",
language = "English (US)",
volume = "65",
pages = "265--272",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells

AU - Street, Daron

AU - Kaufmann, Andreas M.

AU - Vaughan, Andrew T M

AU - Fisher, Susan G.

AU - Hunter, Michael

AU - Schreckenberger, Carola

AU - Potkul, Ronald K.

AU - Gissmann, Lutz

AU - Qiao, Liang

PY - 1997/5

Y1 - 1997/5

N2 - Recently we have demonstrated that tumor-specific cytotoxic T lymphocytes (Culs) can be activated by cervical carcinoma cells expressing the costimulatory molecule CD80, which may be used as a therapeutic vaccine for patients with cervical cancer. For activated Culs to be effective, appropriate amounts of MHC class I expression are required on target tumor cells. In this study, we found that some cervical carcinoma cells expressed only low levels of MHC class 1 and adhesion molecules such as CD54. We further demonstrated that tumor cells (CaSki and SiHa) expressing low levels of MHC class 1 were more resistant to lysis by specific Culs than tumor cells (HeLa) expressing high levels of MHC class I. Treatment of CaSki or SiHa cells with interferon-γ resulted in n increased expression of MHC class I, MHC class II, and CD54. Expression of CD58 and CD80 was not up-regulated or induced. Treatment of the tumor cells with interferon-γ significantly enhanced the lysis of the tumor cells by specific Culs which had been activated by the respective CD80-expressing tumor cells. The enhancement of cytolysis could be blocked by monoclonal antibodies to MHC class I and CD54, but not by that to MHC class II. Furthermore, we found that interferon-γ induced apoptosis in cervical carcinoma cells but not in tumor-specific Culs.

AB - Recently we have demonstrated that tumor-specific cytotoxic T lymphocytes (Culs) can be activated by cervical carcinoma cells expressing the costimulatory molecule CD80, which may be used as a therapeutic vaccine for patients with cervical cancer. For activated Culs to be effective, appropriate amounts of MHC class I expression are required on target tumor cells. In this study, we found that some cervical carcinoma cells expressed only low levels of MHC class 1 and adhesion molecules such as CD54. We further demonstrated that tumor cells (CaSki and SiHa) expressing low levels of MHC class 1 were more resistant to lysis by specific Culs than tumor cells (HeLa) expressing high levels of MHC class I. Treatment of CaSki or SiHa cells with interferon-γ resulted in n increased expression of MHC class I, MHC class II, and CD54. Expression of CD58 and CD80 was not up-regulated or induced. Treatment of the tumor cells with interferon-γ significantly enhanced the lysis of the tumor cells by specific Culs which had been activated by the respective CD80-expressing tumor cells. The enhancement of cytolysis could be blocked by monoclonal antibodies to MHC class I and CD54, but not by that to MHC class II. Furthermore, we found that interferon-γ induced apoptosis in cervical carcinoma cells but not in tumor-specific Culs.

UR - http://www.scopus.com/inward/record.url?scp=0031149531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031149531&partnerID=8YFLogxK

U2 - 10.1006/gyno.1997.4667

DO - 10.1006/gyno.1997.4667

M3 - Article

VL - 65

SP - 265

EP - 272

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -